The Latest Updates from ReSPECT Clinical Trials

As we continue to honor GBM Awareness Day, Plus Therapeutics is proud to spotlight new insights from our RESPECT-GBM Phase 2 clinical trial—research aimed at addressing the urgent need for better treatment options for patients with recurrent glioblastoma (GBM). In a...

Today marks GBM Awareness Day, an important opportunity to raise awareness about glioblastoma (GBM)—an aggressive and life-threatening brain cancer that continues to pose significant challenges for patients, families, and clinicians worldwide. At Plus Therapeutics, we...

We are proud to highlight one of Plus Therapeutics’ leading Principal Investigators, Andrew Brenner, M.D., Ph.D., who recently appeared on KABB News to speak with Melissa Vega about the challenges and advancements in treating glioblastoma (GBM) — one of the most...

Dr. Andrew Brenner Discusses Glioblastoma and REYOBIQ™ on KABB News Andrew Brenner, M.D., Ph.D., one of Plus Therapeutics’ Principal Investigators for the RESPECT-GBM clinical trial, recently appeared on KABB News with Melissa Vega to discuss the ongoing battle...

At Plus Therapeutics, advancing treatment for patients with recurrent glioblastoma (GBM) requires collaboration with some of the brightest minds in brain cancer research and neurosurgery. Today, we’re proud to feature one of our esteemed RESPECT-GBM Principal...

Spotlight on Dr. Toral Patel: Leading Brain Tumor Surgeon and Principal Investigator in the ReSPECT-GBM Clinical Trial As part of our ongoing commitment to highlight the incredible medical professionals behind the ReSPECT-GBM clinical trial, today we are proud to...

Each year, Brain Tumor Awareness Day serves as a critical reminder of the challenges faced by brain cancer patients, and the urgent need for continued research, innovation, and advocacy. At Plus Therapeutics, we are proud to stand alongside passionate individuals and...

Honoring Brain Tumor Awareness Day: Supporting Glioblastoma Patients Through Advocacy and Innovation Today is Brain Tumor Awareness Day—a day dedicated to raising awareness for those affected by brain tumors and honoring the patients, caregivers, and advocates working...

New Coverage: Rhenium Obisbemeda Shows Promise in Recurrent Glioblastoma – Q&A with Dr. Andrew Brenner A new article by Ariana Pelosci at Cancer Network highlights promising data from Plus Therapeutics’ ongoing Phase 1/2 ReSPECT-GBM clinical trial, which is...

Honoring National Gray Day: Advancing Brain Cancer Awareness and Research Today marks National Gray Day, a powerful observance during Brain Cancer Awareness Month dedicated to honoring the lives lost to brain cancer and standing in solidarity with patients, survivors,...